Novavax, Inc. (NASDAQ:NVAX) Position Raised by JPMorgan Chase & Co

Paterniano Del Favero
Luglio 25, 2017

Narrowing in, the stock is at a distance of -5.36% from the 50 day high and 38.66% off of the 50 day low. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Institutional investors and hedge funds own 50.04% of the company's stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Novavax during the fourth quarter valued at approximately $3,300,000. Metropolitan Life Insurance Co. State Street Corp raised its position in Novavax by 99.2% in the fourth quarter. The company trades on average around 638000 shares per market session. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company's stock valued at $3,073,000 after buying an additional 371,295 shares during the period. State Street Corp now owns 19,971,040 shares of the biopharmaceutical company's stock worth $25,163,000 after buying an additional 9,947,481 shares in the last quarter. NY raised its stake in Novavax by 2.9% in the fourth quarter. Finally, Geode Capital Management LLC increased its stake in Novavax by 18.3% in the first quarter. (NASDAQ:NVAX) opened at 1.48 on Monday. A stock with a price that fluctuates wildly, hits new highs and lows or moves erratically is considered highly volatile.

Novavax, Inc. (NASDAQ:NVAX) saw a significant drop in short interest in June.

Novavax Inc (NASDAQ:NVAX) shares traded -1.99% down during most recent session to reach at the closing price of $1.48. The company beat the analyst EPS Estimate with the difference of $-0.04. The business had revenue of $5.68 million for the quarter, compared to analyst estimates of $6.17 million. During the same period a year ago, the firm earned ($0.29) EPS. NY now owns 203,996 shares of the biopharmaceutical company's stock valued at $257,000 after buying an additional 5,704 shares in the last quarter. Previously Novavax Inc (NASDAQ:NVAX) reported $-0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $-0.17 by $0.01 with surprise factor of 5.9%. KCG Holdings Inc. boosted its position in Novavax by 161.0% in the first quarter. If you are accessing this story on another site, it was illegally stolen and republished in violation of US & worldwide copyright and trademark legislation.

Novavax, Inc. (NVAX) shows its Return on Assets (ROA) value of -56.7 percent, while the Return on Equity (ROE) value is -787.4 percent and Return on Investment (ROI) value stands at 0 percent. The Mean Recommendation is the average rating on a stock by the analyst community. The stock has a consensus rating of "Hold" and an average target price of $5.56. Zacks Investment Research downgraded shares of Novavax from a buy rating to a hold rating in a research note on Friday, June 9th. Ladenburg Thalmann Financial Services restated a "neutral" rating on shares of Novavax in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. Their average price target spell out an upbeat performance - a 20% and would give NVAX a market capitalization of almost $513.19M.

In other Novavax news, insider Stanley C. Erck bought 50,000 shares of the business's stock in a transaction that occurred on Thursday, May 11th. (NVAX). Average true range (ATR-14) of the company is at 0.11. Following the purchase, the insider now owns 128,279 shares of the company's stock, valued at approximately $107,754.36. Over the last 90 days, insiders bought 105,000 shares of company stock worth $90,800. Corporate insiders own 4.00% of the company's stock.

Altre relazioni OverNewsmagazine

Discuti questo articolo